Last reviewed · How we verify

Juvenile psoriatic arthritis — Treatment Landscape & Competitive Intelligence

Juvenile psoriatic arthritis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Juvenile psoriatic arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xeljanz tofacitinib Pfizer JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Xeljanz Tofacitinib Citrate Pfizer JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Tasocitinib Tasocitinib Pfizer Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Juvenile psoriatic arthritis
  2. · 1 drug in Juvenile psoriatic arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Juvenile psoriatic arthritis:

Cite this brief

Drug Landscape (2026). Juvenile psoriatic arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/juvenile-psoriatic-arthritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing